Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib versus chemotherapy in FGFR-positive previously platinum-treated advanced urothelial carcinoma
MOH_2018-05-09_002174Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rogaratinib in transitional cell carcinoma (TCC) (2 arms), sponsored by Bayer. Started Feb 2018; status: completed.
02
Drugs
rogaratinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2018-05-09_002174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-09_002174.